real world evidence rwe real world data rwd webinar programmers drug development Wisdom from the Front Lines of Successful NDA Submission Statistical Clinical Programming biostatistics cro mms holdings vendor services pharmaceutical industry biotech

MMS is proud to present our latest webinar – Wisdom from the Front Lines of Successful NDA Submission Programming: Utilizing the Biometrics Operational Data Model.

In this free, on-demand webinar you will discover:

  • The Biometrics Operational Data Model and explain how submission work can be streamlined across programmers and statisticians
  • Validation needs within a submission
  • The importance of reviewer’s guides and when they should be built
  • Why the NDA submission should be considered during early phases
  • Trial domains and how they relate to SDTM, ADaM, and TLFs
  • Items that are easy to overlooked during submission planning

Panelists include:

  • Jim Bademian, Global Head of Statistical Programming, MMS, North Carolina
  • Susheel Arkala, Principal Clinical Programmer and Associate Manager of Programming, MMS, Oregon
  • Chris Hurley, Senior Manager of Global Data Operations, Standards and Systems, MMS, Michigan

View the webinar here

Wisdom from the Front Lines of Successful NDA Submission Programming mms holdings webinar pharma cro biostatistics clinical statistical

Run time: 40:47

Suggested For You

perspectives

May 13th, 2026

Beyond Data Cleaning: A Strategic Shift for Clinical Data Management under ICH E6 (R3)

perspectives

May 5th, 2026

A Statistician's Reflection: FDA Guidance on Limiting Crossover in Oncology Studies 

perspectives

April 27th, 2026

From Stigma to Signal: The Executive Order, CNPV Vouchers, and What Comes Next for Psychedelics

perspectives

April 20th, 2026

The FDA Drug Shortage List Signals Deeper Concerns for the US Medicine Supply Chain

perspectives

April 15th, 2026

Decision-Making in Early-Phase Oncology Trials: Navigating Uncertainty with Evidence Frameworks

perspectives

April 8th, 2026

Four Pillars of My Success as a Clinical Trial Transparency Specialist

perspectives

March 25th, 2026

REMS and Labeling Are Strategic Design Decisions, Not Late-Stage Add-Ons

perspectives

March 12th, 2026

AI in Pharma: Autopilot Is Not the Same as Removing the Pilot 

perspectives

March 3rd, 2026

Modeling and Simulation in Clinical Trials: A Practical Approach to De-Risking Study Design

perspectives

February 25th, 2026

Integrating AI and Automation Into Clinical Trial Operations With Discipline and Transparency

perspectives

February 10th, 2026

A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development 

perspectives

February 3rd, 2026

A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development